Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Protagonist Therapeutics Inc’s stock clocked out at $40.24, down -0.17% from its previous closing price of $40.31. In other words, the price has decreased by -$0.17 from its previous closing price. On the day, 0.61 million shares were traded. PTGX stock price reached its highest trading level at $40.88 during the session, while it also had its lowest trading level at $39.91.
Ratios:
To gain a deeper understanding of PTGX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.20 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.27. For the most recent quarter (mrq), Quick Ratio is recorded 13.73 and its Current Ratio is at 13.73. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, CapitalOne on October 30, 2023, initiated with a Overweight rating and assigned the stock a target price of $32.
On August 25, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $21.JMP Securities initiated its Mkt Outperform rating on August 25, 2022, with a $21 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jul 24 ’24 when Waddill William D. sold 8,000 shares for $40.00 per share. The transaction valued at 320,000 led to the insider holds 12,000 shares of the business.
Waddill William D. sold 8,000 shares of PTGX for $280,000 on Jun 07 ’24. The Director now owns 12,000 shares after completing the transaction at $35.00 per share. On Jun 07 ’24, another insider, PATEL DINESH V PH D, who serves as the President and CEO of the company, sold 35,000 shares for $35.19 each. As a result, the insider received 1,231,650 and left with 515,415 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 2370321152 and an Enterprise Value of 1817294464. As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 15.32. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.43 while its Price-to-Book (P/B) ratio in mrq is 4.37. Its current Enterprise Value per Revenue stands at 5.695 whereas that against EBITDA is 11.862.
Stock Price History:
The Beta on a monthly basis for PTGX is 2.14, which has changed by 1.1461334 over the last 52 weeks, in comparison to a change of 0.24822903 over the same period for the S&P500. Over the past 52 weeks, PTGX has reached a high of $42.67, while it has fallen to a 52-week low of $13.72. The 50-Day Moving Average of the stock is 13.73%, while the 200-Day Moving Average is calculated to be 46.94%.
Shares Statistics:
It appears that PTGX traded 960.49K shares on average per day over the past three months and 718440 shares per day over the past ten days. A total of 57.71M shares are outstanding, with a floating share count of 55.64M. Insiders hold about 5.55% of the company’s shares, while institutions hold 99.95% stake in the company. Shares short for PTGX as of 1722384000 were 2903461 with a Short Ratio of 3.02, compared to 1719532800 on 2039947. Therefore, it implies a Short% of Shares Outstanding of 2903461 and a Short% of Float of 5.0.
Earnings Estimates
The market rating for Protagonist Therapeutics Inc (PTGX) is a result of the insights provided by 6.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.28, with high estimates of $1.03 and low estimates of -$0.73.
Analysts are recommending an EPS of between $3.03 and $1.32 for the fiscal current year, implying an average EPS of $1.78. EPS for the following year is -$1.67, with 5.0 analysts recommending between $1.74 and -$3.25.
Revenue Estimates
A total of 6 analysts have provided revenue estimates for PTGX’s current fiscal year. The highest revenue estimate was $374M, while the lowest revenue estimate was $259.1M, resulting in an average revenue estimate of $284.92M. In the same quarter a year ago, actual revenue was $60M